Saffron (Crocus sativus)
Saffron (Crocus sativus stigma) is a botanical standardized extract with SSRI-comparable performance for mild-to-moderate depression. Akhondzadeh 2005 established non-inferiority to fluoxetine on HAM-D; Lopresti 2019 meta-analysis confirmed mood SMD; Ghajar 2017 showed GAD benefit.
Saffron (Crocus sativus) scored 7.3 / 10 (💪 Strong recommend) on the BioHarmony scale as a Substance → Botanical Extract (non-adaptogenic).
What It Is
Saffron is the dried stigma of Crocus sativus, a fall-blooming crocus cultivated primarily in Iran, India, Spain, and Greece. Each flower produces three stigmas, and roughly 150,000 flowers are required to yield one kilogram of finished spice, which is why saffron is the most expensive culinary botanical in the world and also why adulteration is systemic. The four bioactive compounds that carry the clinical effects are crocin (the carotenoid responsible for color), crocetin (crocin's aglycone form), safranal (the volatile aromatic), and picrocrocin (the bitter precursor to safranal). Standardized extracts like affron and Satiereal fingerprint these compounds and normalize dose, which is what makes the clinical literature replicable across labs.
Mechanistically saffron is one of the more polypharmacological botanicals studied in modern psychiatry. Crocin and safranal produce reuptake inhibition at serotonin, dopamine, and norepinephrine transporters at affinities comparable to pharmaceutical SSRIs; safranal contributes additional NMDA antagonism and GABA-A agonism; and the combined extract demonstrates measurable HPA-axis modulation with cortisol attenuation under chronic stress. On the neurotrophic side, crocin upregulates BDNF in hippocampal tissue, which plausibly underwrites the Alzheimer's memory-preservation signal. On the retinal side, crocin acts as a direct antioxidant at photoreceptors and stabilizes macular pigment, which is the mechanism behind the Falsini 2010 and Broadhead 2019 AMD results.
The clinical footprint is unusually broad for a botanical. Lopresti 2019 meta-analyzed depression RCTs and confirmed SMD favoring saffron with effect sizes that rival pharmaceutical antidepressants in mild-to-moderate cases. Akhondzadeh 2005 established non-inferiority to imipramine on HAM-D. Ghajar 2017 did the same for generalized anxiety disorder against citalopram. PMS, menopausal mood, sleep-quality, and AMD all have their own dedicated RCTs. The two evidence-integrity caveats are the geographic concentration (a large fraction of depression RCTs come from the Akhondzadeh lab in Tehran) and the industry-funding pattern for mood and sleep trials (Pharmactive Biotech funds most affron work). EFSA rejected the affron health claim in 2021 on these grounds. Independent AMD replication is the strongest non-industry signal.
Type: Botanical traditional extract (Crocus sativus stigma; crocin + safranal + picrocrocin bioactives; OTC supplement).
Current status: Nick is actively using saffron, but almost always as part of a multi-ingredient stack rather than standalone.
Terminology
- Crocin: Primary carotenoid bioactive in Crocus sativus stigma; responsible for saffron's golden color and for serotonin-dopamine-norepinephrine reuptake modulation and BDNF upregulation.
- Safranal: Volatile aromatic bioactive; contributes NMDA antagonism and GABA-A agonism, underwriting the anxiolytic arm of saffron's effect.
- Picrocrocin: Bitter precursor to safranal; contributes flavor and is a biomarker of authentic saffron in adulteration testing.
- HAM-D (Hamilton Depression Rating Scale): Clinician-administered 17-item depression severity instrument; the primary outcome in Akhondzadeh 2005 and most saffron depression RCTs.
- SSRI: Selective serotonin reuptake inhibitor (fluoxetine, citalopram, sertraline). Saffron's primary pharmaceutical comparator class.
- NMDA: N-methyl-D-aspartate receptor. Safranal antagonism at NMDA underwrites anxiolytic and neuroprotective effects.
- HPA axis: Hypothalamic-pituitary-adrenal axis. Saffron modulates HPA tone and attenuates cortisol under chronic stress.
- GAD: Generalized anxiety disorder. Studied in Ghajar 2017 vs citalopram; HAM-A non-inferiority demonstrated.
- PMS: Premenstrual syndrome. Saffron 15 mg BID cyclically reduces symptom burden (Agha-Hosseini 2008).
- AMD: Age-related macular degeneration. Saffron 20 mg/day shows retinal stabilization in Falsini 2010 and Broadhead 2019.
- Dry vs wet AMD: Dry AMD is the non-exudative atrophic form (~85% of cases); wet AMD involves choroidal neovascularization. Saffron RCT support is for early and mild dry AMD, not wet.
- affron: Pharmactive Biotech's standardized saffron extract (3.5% Lepticrosalides); most-studied formulation for mood and sleep.
- Satiereal: Inoreal's standardized saffron extract for appetite regulation; dosed at 176 mg/day, distinct evidence base from affron.
- Crocus sativus: Binomial name of the saffron crocus; the stigma is the only commercially used plant part.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 2 routes and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral capsule (standardized extract) | Capsule or tablet, 14-30 mg standardized extract (affron, Satiereal, Crocin-1) | 28-30 mg/day (mood); 176 mg/day Satiereal (satiety); 20 mg/day (AMD) | 14-88 mg/day |
| Oral powder (whole stigma brewed as tea) | Loose stigma infusion or encapsulated whole-stigma powder | 100-200 mg/day whole stigma (equivalent bioactive load to 28-30 mg extract only when standardization is verified) | 50-400 mg/day |
Protocols
Standard depression protocol Clinical
- Dose
- 28-30 mg/day standardized extract (affron 28 mg or equivalent)
- Frequency
- Once daily, morning with or without food
- Duration
- Minimum 6-8 weeks; typical continuous use
Canonical Akhondzadeh + Lopresti dose. Non-inferior to fluoxetine 20 mg/day and imipramine 100 mg/day across 8 RCTs.
PMS cyclic protocol Clinical
- Dose
- 15 mg twice daily (30 mg total)
- Frequency
- Twice daily for 14 days pre-menses, off during menses
- Duration
- 2-3 menstrual cycles minimum
Agha-Hosseini 2008 regimen. Targets luteal-phase mood, irritability, and somatic symptoms.
AMD retinal preservation protocol Clinical
- Dose
- 20 mg/day standardized extract
- Frequency
- Once daily
- Duration
- 3-12 months; continuous while disease is active
Falsini 2010 and Broadhead 2019 protocol. BCVA +0.69 letters and mfERG density gains at 3 months; regresses on washout.
Satiereal satiety protocol Clinical
- Dose
- 176.5 mg/day Satiereal (standardized for safranal)
- Frequency
- 88 mg pre-breakfast and 88 mg pre-afternoon snack
- Duration
- 8 weeks minimum
Distinct formulation optimized for appetite regulation rather than mood. Effect size small; not a primary weight-loss tool.
Sleep-quality evening protocol Clinical
- Dose
- 100 mg affron or 28 mg standardized extract
- Frequency
- Once daily, 60-90 minutes before bed
- Duration
- 4-8 weeks
Lopresti 2020 and Pachikian 2021 regimens. PSQI mean difference -2.14 and actigraphy-confirmed total sleep duration gains.
How this score is calculated →
Upside (2.54 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.7 | 0.925 | |
| Breadth of Benefits | 15% | 4.2 | 0.630 | |
| Evidence Quality | 25% | 3.3 | 0.825 | |
| Speed of Onset | 10% | 3.5 | 0.350 | |
| Durability | 10% | 2.8 | 0.280 | |
| Bioindividuality Upside | 15% | 3.5 | 0.525 | |
| Total | 3.535 |
Upside Rationale
Efficacy (3.7/5.0). Depression RCTs show Cohen's g = 0.99 to 1.62 versus placebo, and non-inferior to fluoxetine and imipramine (SMD = 0.10, NS) across 8 meta-analyzed trials. Sleep quality improves meaningfully (PSQI mean difference -2.14, ISI MD -2.63 across 8 RCTs, N=611). AMD retinal stabilization at 20 mg/day (+0.69 BCVA letters, mfERG density gains) is smaller but clinically meaningful over 3 to 12 months. Glycemic effects are modest (FPG -8.42 mg/dL, HbA1c -0.22%). The large mood effect sizes are suspicious because supplement research rarely produces d greater than 1.0 cleanly, and Nick's real-world experience is meaningful but not transformative: "definite noticeable effects on mood and creative thinking." Settled mid-high.
Breadth of Benefits (4.2/5.0). Mood, anxiety, sleep, cognition, ADHD, PMS/PMDD, sexual function, AMD/vision, glycemic control, and appetite. Dominated by CNS and eye but genuinely multi-system. The breadth is the structural reason saffron slots into so many stacks; each pillar has at least one RCT even when effect sizes are small. Mechanistic polypharmacology (serotonergic, dopaminergic, GABAergic, NMDA, HPA, BDNF, retinal antioxidant) underwrites the breadth rather than a single shotgun pathway, which is why the benefits across systems look coherent rather than coincidental.
Evidence Quality (3.3/5.0). 50+ RCTs, multiple meta-analyses, Cochrane-adjacent reviews, centuries of documented Persian medicine use. BUT: a large fraction of depression, cognition, ADHD, and sexual function trials come from a single Iranian research group (Akhondzadeh lab), affron mood and sleep trials are heavily industry-funded by Pharmactive Biotech, and publication bias was detected in both Hausenblas (depression) and Khorasani 2024 (FPG) meta-analyses. EFSA rejected affron's health claim in 2021 for insufficient efficacy evidence. Independent AMD replication (Falsini Italy and Broadhead Australia) is the strongest non-industry signal. Base score ~4.0 minus 0.7 for geographic concentration and industry funding.
Speed of Onset (3.5/5.0). Mood effects typically noticeable at 1 to 3 weeks, PMS/PMDD resolves over 2 menstrual cycles, AMD benefit measurable at 3 months. Faster than most psychiatric tools (SSRIs typically require 4-6 weeks for full effect). Sleep-quality improvements appear at 2-4 weeks on 28 mg/day. Onset is dose-responsive: 14 mg/day starts work slightly later than 28-30 mg/day but catches up by week 8. Among botanicals, saffron is one of the faster-acting mood tools.
Durability (2.8/5.0). Benefits hold on continued use (up to 14 months in trials) but AMD regresses to baseline on washout, and mood effects likely require ongoing dosing. Nothing permanent. This is the inverse of an intervention like creatine, where long-term storage buffers short-term stopping: saffron's mechanism depends on ongoing reuptake modulation and cofactor availability, so chronic dosing is the implicit protocol. No published evidence of adaptation or efficacy loss at 12-14 months.
Bioindividuality Upside (3.5/5.0). Responder rate in clean community reports tracks RCTs reasonably well (~50 to 60%) when adulterated products are excluded. Wide demographic applicability: women with PMS/PMDD, older adults for vision, general population for mood and sleep. Nick notes it balances multiple stacks, suggesting a broad synergy profile. Genetic and biomarker responder predictors are not established, but clean responders tend to be mild-to-moderate baseline severity on whichever endpoint is being targeted. Severe depression non-responders are well-documented in the Akhondzadeh literature.
Downside (0.75 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 2.0 | 0.600 | |
| Side Effect Profile | 15% | 1.8 | 0.270 | |
| Financial Cost | 5% | 1.5 | 0.075 | |
| Time/Effort Burden | 5% | 1.2 | 0.060 | |
| Opportunity Cost | 5% | 1.3 | 0.065 | |
| Dependency / Withdrawal | 15% | 1.2 | 0.180 | |
| Reversibility | 25% | 1.2 | 0.300 | |
| Total | 1.550 | |||
| Harm subtotal × 1.4 | 1.890 | |||
| Opportunity subtotal × 1.0 | 0.200 | |||
| Combined downside | 2.090 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.750 |
Downside Rationale
Safety Risk (2.0/5.0). Oral LD50 in mice ~4,120 mg/kg, extrapolating to ~20 to 67g in a 60kg human. Toxic effects emerge at 1.2 to 2g; pharmacopoeias cite 5g as the toxic threshold. Supplement doses of 28 to 88 mg/day sit 60 to 180x below the toxic threshold. Zero fatal or permanently disabling events documented at supplement doses in any RCT. Catastrophic risk floor is NOT triggered. Real concerns: pregnancy contraindication (10.6% vs 0% miscarriage rate in Iranian saffron field worker cohort, mechanistically confirmed in animal models, screenable), documented hypomania case reports in bipolar patients at 8 weeks that should be treated as a hard contraindication, and theoretical SSRI interaction (crocin + safranal hit SERT/NET/DAT/MAO though no confirmed serotonin syndrome at supplement doses).
Side Effect Profile (1.8/5.0). Mild and transient: nausea, GI distress, appetite changes, dry mouth, drowsiness, headache. Consistently fewer than SSRI comparators across head-to-head trials. Most events resolve within the first 1-2 weeks and do not force discontinuation. Dry mouth and mild drowsiness are the two most prevalent complaints in affron trials. No weight gain signal. No sexual side effects (inverse of SSRI class profile). Rash and allergic reactions are rare but documented in hypersensitive individuals, most often in those with known Iridaceae family allergies.
Financial Cost (1.5/5.0). Quality standardized extract runs ~$0.38 to $1/day ($12 to $30/month). Cheap for what it delivers. Branded affron and Satiereal sit at the top end ($30 to $60/month); generic third-party-tested extracts bring the floor under $15/month. Per v0.5 accessible-channel cost rules, scored at the generic third-party-tested tier rather than branded retail. Sourcing-quality premium is justified given adulteration data and should not be confused with brand markup.
Time/Effort Burden (1.2/5.0). One or two capsules daily. Effectively zero friction. No cycling, no timing complexity, no food-pairing requirements. Compatible with existing AM or PM supplement rituals and does not require refrigeration, blood-draw monitoring, or titration tracking. The only administrative burden is verifying sourcing quality, which is a one-time decision rather than a daily task. For split-dose protocols (common for anxiety), the evening dose adds ten seconds to an existing routine. Total lifetime cognitive load is trivial compared with rapamycin cycling, GLP-1 injection logistics, or peptide reconstitution workflows.
Opportunity Cost (1.3/5.0). Complements most nootropic and mood stacks (Nick runs it alongside magnesium, theanine, and adaptogens). The main conflict is St. John's Wort and bupropion, which are rarely in the same stacks anyway. Saffron does not displace other stack items; it layers additively with them. The only meaningful opportunity cost is for users who would otherwise prioritize a fully evidence-proven SSRI under clinician care for severe depression, where saffron is not a validated substitute and delaying effective treatment has real cost.
Dependency/Withdrawal (1.2/5.0). No tolerance demonstrated across 14-month trials. No documented withdrawal syndrome in any RCT or community surveillance channel. Abrupt cessation is unremarkable across user reports, and dose-escalation patterns do not appear in long-term follow-up data. Per v0.5 dependency framework, this is the substrate-class floor: no receptor downregulation evidence despite the serotonergic mechanism, no HPA rebound on stopping, and no physiological dependence signals in any comparator arm. Users stopping saffron typically describe the return of prior mood baseline within 2-3 weeks, which is consistent with pharmacokinetic washout rather than withdrawal.
Reversibility (1.2/5.0). Fully reversible. Washout returns to baseline within weeks across every endpoint studied. No lingering effects documented in any RCT follow-up. AMD benefits regress to baseline on stopping, which is a durability concern but a reversibility strength because nothing accumulates that cannot be unwound, including no persistent methylation changes, no stored lipid burden, and no receptor remodeling. Mood and sleep benefits fade over 1-3 weeks post-cessation. This clean reversibility is structurally why saffron is low-risk as a trial intervention: if it does not work for a given individual, stopping is fast and complete.
Verdict
Best for: Adults with mild-to-moderate low mood, PMS/PMDD, sleep fragmentation, early AMD, or anyone building a low-risk stack that wants a serotonergic tone without SSRI side effects. Particularly useful as an SSRI-adjunct or tapering support tool under clinician guidance. Nick's own use case (stack balancer for mood and creative thinking) is a representative success pattern.
Avoid if: Pregnant or trying to conceive (hard contraindication, abortifacient). Taking an MAOI (theoretical but real mechanistic stack). History of bipolar disorder (mania flip risk). On warfarin or active bleeding disorder (mild antiplatelet signal). Sourcing from unverified suppliers (saffron is one of the most adulterated spices globally; 20/104 commercial samples in a 2025 review contained Sudan I-IV genotoxic dyes or Rhodamine B). Stick with third-party-tested standardized extracts (affron, Satiereal, Nootropics Depot HP).
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| 💪 Mood / Emotional Regulation | 7.8 | Non-inferior to fluoxetine/imipramine across 8 RCTs, g=0.99-1.62 vs placebo, fewer AEs than SSRIs |
| 💪 Depression | 7.8 | Non-inferior to fluoxetine/imipramine; g=0.99-1.62 vs placebo across meta-analyzed trials |
| 💪 Eye / Vision Health | 7.2 | AMD retinal stabilization independently replicated by Falsini (Italy) and Broadhead (Australia); BCVA +0.69 letters, mfERG gains |
| 💪 Sleep Quality | 7.0 | PSQI MD -2.14, ISI MD -2.63 across 8 RCTs, N=611, actigraphy-confirmed in Pachikian 2021 |
| 👍 Anxiety | 6.5 | Multiple RCTs show anxiety reduction, smaller effect than depression |
| 👍 Stress / Resilience | 6.0 | HPA-axis modulation demonstrated; cortisol reductions in some trials |
| 👍 Neuroprotection | 6.0 | BDNF upregulation and anti-neuroinflammatory action; Alzheimer's clinical trials support |
| 👍 Geriatric / Aging Population | 6.0 | AMD, Alzheimer's memory preservation, and mood data align with older-adult use cases |
| ⚖️ Cognition / Focus | 5.5 | Mixed healthy-adult cognition data; indirect via mood improvement |
| ⚖️ Memory | 5.5 | Alzheimer's RCTs show memory preservation non-inferior to donepezil (Akhondzadeh 2010) |
| ⚖️ Libido / Sexual Health | 5.5 | Positive RCT results for SSRI-induced sexual dysfunction and ED |
| ⚖️ Antioxidant / Oxidative Stress | 5.5 | Crocin/crocetin are potent antioxidants; well-documented in vitro and animal |
| ⚖️ Sleep Architecture (Deep/REM) | 5.0 | Self-reported and actigraphy improvements; minimal PSG data on stages |
| ⚖️ Hormonal / Endocrine | 5.0 | PMS/PMDD effect suggests hormonal modulation; estrogen/progesterone pathways implicated |
| ⚖️ Neuroplasticity | 5.0 | BDNF upregulation supports plasticity; clinical endpoints limited to mood/cognition |
| ○ Creativity / Divergent Thinking | 4.5 | Anecdotal reports and Nick's own N=1 suggest creative-thinking effects; no RCT data |
| ○ Metabolic Health | 4.5 | Modest glycemic effect: FPG -8.42 mg/dL, HbA1c -0.22%; publication bias flagged |
| ○ Blood Sugar / Glycemic Control | 4.5 | Small but consistent glycemic improvement across 10 RCTs, N=562 |
| ○ Healthspan | 4.5 | Mood, sleep, and vision preservation contribute to healthspan; no hard data |
| ○ Anti-Inflammatory | 4.5 | NF-kB / TNF-alpha suppression demonstrated; weak clinical endpoints |
| ○ Fertility (Male) | 4.5 | Small RCTs suggest benefit in erectile dysfunction; heterogeneous quality |
| ○ Cardiovascular | 4.0 | Mild BP reduction and lipid signals; no hard outcomes |
| ○ Flow State / Peak Mental Performance | 3.5 | No direct flow-state research; indirect via mood/cognition |
| ○ Body Composition / Fat Loss | 3.5 | Satiereal shows mild appetite suppression; effect small and short-term |
| ○ Longevity / Lifespan | 3.5 | Mechanistic plausibility via antioxidant/anti-inflammatory pathways; no direct longevity endpoints |
| ○ Mitochondrial | 3.5 | Mechanistic antioxidant support; weak direct mitochondrial data |
| ○ Chronic Pain Management | 3.5 | Dysmenorrhea and chronic pain RCTs show small effects |
| ○ HRV / Vagal Tone / Autonomic Balance | 3.5 | Mechanistic via HPA modulation; no direct HRV RCTs |
| ○ Circadian Rhythm / Chronobiology | 3.5 | Indirect via sleep-quality improvements; no direct DLMO data |
| ○ Energy / Fatigue | 3.0 | No direct energy RCTs; indirect via mood improvement |
| ○ Reaction Time / Coordination | 3.0 | Indirect via mood and cognition |
| ○ Social Bonding / Empathy | 3.0 | Indirect via mood and serotonergic tone |
| ○ Pediatric Use | 3.0 | Small ADHD pediatric RCTs; otherwise limited |
Frequently Asked Questions
How does saffron actually work for depression?
Saffron acts across at least six pathways simultaneously. Crocin and safranal produce serotonin, dopamine, and norepinephrine reuptake inhibition at receptor-level affinities comparable to SSRIs. Safranal contributes NMDA antagonism and GABA-A agonism, which anchors its anxiolytic arm. HPA-axis modulation attenuates cortisol output under stress, and crocin upregulates BDNF in hippocampal tissue. The polypharmacology is why Akhondzadeh 2005 found 30 mg/day non-inferior to fluoxetine and imipramine with fewer adverse events across 8 head-to-head trials.
Is saffron as effective as an SSRI for mild-to-moderate depression?
For mild-to-moderate depression, the head-to-head evidence supports it. The Lopresti 2019 meta-analysis confirmed saffron SMD favoring active over placebo, with Cohen's g of 0.99 to 1.62 across RCTs. Direct comparisons to fluoxetine 20 mg/day and imipramine 100 mg/day showed non-inferiority on the Hamilton Depression Rating Scale (HAM-D). The caveats are real: a large share of the trials come from one Iranian research group, publication bias is documented in the Hausenblas 2013 funnel plot, and EFSA rejected the affron-branded health claim in 2021. For severe depression, saffron is not validated.
What does saffron do for anxiety, PMS, and menopausal symptoms?
Saffron has RCT support across all three. Ghajar 2017 showed saffron 30 mg/day non-inferior to citalopram 40 mg/day for generalized anxiety disorder on HAM-A across 12 weeks. Agha-Hosseini 2008 (15 mg twice daily, 2 cycles) reduced PMS symptom burden meaningfully against placebo. Kashani 2018 showed improvements in post-menopausal mood and hot-flash burden at 30 mg/day. Effect sizes are smaller than depression but consistent across independent labs. Onset runs 2-3 cycles for PMS and 4-8 weeks for GAD.
Does saffron actually help age-related macular degeneration?
The AMD arm is one of saffron's cleanest signals because of independent international replication. Falsini 2010 in Italy first showed retinal flicker sensitivity gains on 20 mg/day. Broadhead 2019 in Australia independently replicated with best-corrected visual acuity (BCVA) +0.69 letters and multifocal ERG density gains at 3 months. The effect is specific to early and mild dry AMD; it regresses on washout and is not validated for advanced wet AMD. For anyone with an AMD diagnosis, 20 mg/day standardized extract is worth raising with a retinal specialist.
affron vs Satiereal vs whole stigma: which form should I buy?
affron (Pharmactive, standardized to 3.5% Lepticrosalides including crocin and safranal) is the most-studied mood and sleep formulation at 14-28 mg/day. Satiereal (Inoreal) is standardized differently and targets appetite at 176 mg/day; its effect is small and distinct from mood. Crocin-1 isolate is a research-grade single-compound extract. Whole stigma brewed as tea can work but carries the highest adulteration risk because dried saffron threads are commonly cut with safflower, turmeric, and Sudan dyes in unverified supply chains. Default to third-party-tested standardized extract.
Should I avoid saffron if I have bipolar disorder or take an SSRI?
Yes, treat bipolar as a hard contraindication. Case reports document hypomania emergence at 8 weeks on 30 mg/day in susceptible individuals, consistent with the serotonergic and dopaminergic polypharmacology. With SSRIs, saffron has been studied as an adjunct (Shahmansouri 2014 with sertraline in cardiac depression) without serotonin syndrome at supplement doses, but the theoretical interaction is real and co-administration should be clinician-managed. Avoid with MAOIs entirely because crocin and safranal hit MAO in vitro and the combined pharmacological load has never been tested clinically.
How do I titrate saffron and how long until I feel it?
Start at 14 mg/day affron or 15 mg/day standardized extract for the first week, then move to 28-30 mg/day as the target dose. Most users notice mood and stress-buffering effects by weeks 2-4, with full effect at 6-8 weeks. PMS protocols run cyclically (luteal-phase dosing) and typically need 2-3 cycles before effect stabilizes. AMD retinal-function gains appear at 3 months. Splitting 28 mg into AM and evening doses is common for anxiety-dominant presentations where a steady serotonergic tone across the day outperforms a single bolus.
Can I stack saffron with L-theanine, 5-HTP, and other mood tools?
Saffron stacks cleanly with L-theanine, magnesium, and most adaptogens, and this is how Nick uses it in practice. 5-HTP combinations deserve caution because both push serotonergic tone, so start low and space dosing. Avoid saffron with St. John's Wort (additive serotonergic load), bupropion (dopaminergic overlap), and any MAOI. No meaningful interaction with standard nootropic stacks (lion's mane, methylene blue at low dose, creatine, electrolytes). Timing: most users take saffron in the morning and move 5-HTP or magnesium to the evening.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension shifts | New score |
|---|---|---|
| Independent non-Iranian replication of depression effect (multi-lab meta-analysis) | Evidence 3.3 to 4.0, Efficacy 3.7 to 4.0 | 7.5 / 10 (💪 Strong recommend) |
| 2+ year AMD RCT confirms long-term vision preservation | Efficacy 3.7 to 4.0, Durability 2.8 to 3.2 | 7.4 / 10 (💪 Strong recommend) |
| 12-month safety study confirms zero bipolar mania signal | Safety 2.0 to 1.5 | 7.5 / 10 (💪 Strong recommend) |
| Publication-bias-corrected meta-analysis halves depression effect | Evidence 3.3 to 2.5, Efficacy 3.7 to 2.8 | 7.0 / 10 (💪 Strong recommend edge) |
| Pharmactive-funded trials retracted and adulteration epidemic confirmed | Evidence 3.3 to 2.3, Bioindividuality 3.5 to 2.8 | 6.6 / 10 (👍 Worth trying) |
Key Evidence Sources
- Akhondzadeh S, et al. 2005. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial.. Landmark SSRI non-inferiority RCT. 30 mg/day saffron vs imipramine 100 mg/day; HAM-D reductions equivalent, fewer side effects.
- Lopresti AL, Drummond PD. 2019. Efficacy of saffron (Crocus sativus) for depression: a systematic review and meta-analysis.. Meta-analysis confirming SMD favoring saffron for depression. Publication bias and Iranian-group concentration noted.
- Ghajar A, et al. 2017. Crocus sativus L. versus citalopram in the treatment of generalized anxiety disorder: a randomized clinical trial.. GAD RCT, n=60, 12 weeks. Saffron 30 mg/day vs citalopram 40 mg/day. Non-inferior on HAM-A.
- Broadhead GK, et al. 2019. Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial.. Independent Australian AMD replication. BCVA +0.69 letters, mfERG density gains at 3 months.
- Falsini B, et al. 2010. Influence of saffron supplementation on retinal flicker sensitivity in early age-related macular degeneration.. First AMD retinal-function RCT. 20 mg/day for 3 months.
- Hausenblas HA, et al. 2013. Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials.. SMD -1.22 favoring saffron vs placebo; publication bias detected.
- Marx W, et al. 2019. Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis.. Confirmed effect with tighter inclusion criteria; 23 RCTs.
- Kashani L, et al. 2018. Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial.. Menopause-specific mood RCT. Saffron 30 mg/day improved HAM-D and hot-flash burden.
- Agha-Hosseini M, et al. 2008. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial.. PMS RCT. 15 mg BID for 2 cycles. Symptom reduction significantly greater than placebo.
- Lopresti AL, et al. 2020. Effects of saffron on sleep quality in healthy adults with self-reported poor sleep: a randomized, double-blind, placebo-controlled trial.. affron 14 mg and 28 mg; ISI and PSQI improvements.
- Pachikian BD, et al. 2021. Effects of saffron extract on sleep quality: a randomized double-blind controlled clinical trial.. Actigraphy-confirmed sleep duration gains on 15.5 mg/day for 6 weeks.
- Khorasani S, et al. 2024. Saffron on glycemic indices and lipid profile: meta-analysis.. FPG -8.42 mg/dL, HbA1c -0.22%; publication bias flagged.
- Akhondzadeh S, et al. 2010. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial.. Non-inferior to donepezil on ADAS-Cog and CDR-SB.
- EFSA. 2021. Affron health claim evaluation.. EFSA rejected affron's health claim citing insufficient evidence. Material context for evidence-integrity adjustment.
- Systematic review of saffron adulteration. 2025.. 20/104 commercial samples contained Sudan I-IV or Rhodamine B. Sourcing-quality rationale for Verdict Avoid-if clause.
Other interventions for Mood
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.535 − 0.750 = 1.785
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((1.785 + 7) / 12) × 10 = 7.3 / 10
